Researchers have discovered that an experimental drug appears to block the flow of toxic ions thought to cause Alzheimer’s.
Browsing: amyloid beta
For the first time, researchers have been able to examine the exact link between amyloid- β and tau in an animal model of the Alzheimer’s brain, providing hope for new therapeutic targets.
A study has investigated the response from seniors with high risk of Alzheimer’s when told that their brain scans display an ‘elevated’ level of beta amyloid protein plaques, revealing frustrations with the lack of information given.
Studies in aged chimpanzees have identified neuropathological hallmarks similar to those observed in the human Alzheimer’s diseased brain.
Journal Watch: Protective factors differentially affect amyloid pathology and Alzheimer’s disease-pattern neurodegeneration
Recent research led by Vemuri et al. indicates that a variety of risk factors influencing amyloid deposition are distinct from Alzheimer’s disease-pattern neurodegeneration.
The impact of β-amyloid positron emission tomography on the diagnostic and treatment decisions of dementia experts
Amyloid positron emission tomography (aPET) measurement of Alzheimer’s disease (AD) pathology could improve the accurate diagnosis of cognitive disorders.
Neuroscientists demonstrate that deficiency of the immune protein TREM2 has opposing effects at different stages of Alzheimer’s disease progression.
David Howett reviews a recent paper from Hefendehl et al. that reported that the microenvironment surrounding amyloid plaques disrupts neuronal glutamate homeostasis
Researchers have demonstrated a widely used HIV therapy, protease inhibitors, might induce cell stress, leading to the production of beta amyloid and contributing to HIV-associated neurocognitive disorders.
New research has identified how a subset of proteins associated with Alzheimer’s disease can enter and damage retinal cells, and could lead the way to future preventative and treatment strategies for age-related macular degeneration.